Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Bo-Eric Persson"'
Publikováno v:
Therapeutic Advances in Urology, Vol 8 (2016)
Objectives: The objective of this study was to assess differences in efficacy outcomes between luteinizing hormone-releasing hormone (LHRH) agonist plus antiandrogen (AA) flare protection and monotherapy with the gonadotrophin-releasing hormone antag
Externí odkaz:
https://doaj.org/article/7cbe78882ed049f2b6d26be72ceb6ec0
Publikováno v:
Therapeutic Advances in Urology, Vol 7 (2015)
Objective: To evaluate the efficacy of second-line degarelix in patients with prostate cancer (PCa) after treatment failure with a luteinizing hormone-releasing hormone (LHRH) agonist. Methods: This 1-year exploratory, multicentre, open-label phase I
Externí odkaz:
https://doaj.org/article/61d5cfec06cc4abfa5b3ad7e8f4938d3
Publikováno v:
Therapeutic Advances in Urology, Vol 3 (2011)
Androgen deprivation therapy (ADT) is the main treatment approach in advanced prostate cancer and in recent years has primarily involved the use of gonadotropin-releasing hormone (GnRH) agonists. However, despite their efficacy, GnRH agonists have se
Externí odkaz:
https://doaj.org/article/c78820be96264280a962ccd99901bcb7
Publikováno v:
Therapeutic Advances in Urology, Vol 7 (2015)
Objective: To evaluate the efficacy of second-line degarelix in patients with prostate cancer (PCa) after treatment failure with a luteinizing hormone-releasing hormone (LHRH) agonist. Methods: This 1-year exploratory, multicentre, open-label phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65548220cd613ad302f8a2a58829999
https://doi.org/10.1177/1756287215574479
https://doi.org/10.1177/1756287215574479
Autor:
Johan Mesterton, Alexander Liede, Jan Stålhammar, Bo-Eric Persson, Patrik Sobocki, Jonas Banefelt, Rohini K. Hernandez
Publikováno v:
Cancer Epidemiology. 38:442-447
To examine the incidence of metastases and clinical course of prostate cancer patients who are without confirmed metastasis when initiating androgen deprivation therapy (ADT).Retrospective cohort study conducted using electronic medical records from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf86eeaf91f758044d402ef1f7ab4a92
https://doi.org/10.1016/j.canep.2014.04.007
https://doi.org/10.1016/j.canep.2014.04.007
Autor:
Laurence Klotz, Bertrand Tombal, Fritz H. Schröder, Anders Malmberg, E. David Crawford, Tine Kold Olesen, Bo-Eric Persson, Neal D. Shore, Judd W. Moul, Laurent Boccon-Gibod, Kurt Miller
Publikováno v:
Urology, 83(5), 1122-1128. Elsevier Inc.
OBJECTIVE To demonstrate the safety and efficacy of up to 5 years of degarelix treatment and the effects of crossing over from leuprolide to degarelix in the extension phase of a phase III pivotal 1-year trial. METHODS Patients receiving degarelix wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd94e431c3e0d3811eb17f63ab81f4cf
https://hdl.handle.net/1765/59706
https://hdl.handle.net/1765/59706
Publikováno v:
Therapeutic Advances in Urology, Vol 8 (2016)
Objectives: The objective of this study was to assess differences in efficacy outcomes between luteinizing hormone-releasing hormone (LHRH) agonist plus antiandrogen (AA) flare protection and monotherapy with the gonadotrophin-releasing hormone antag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df14aec09a791603e520520cd92929b1
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-317715
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-317715
Autor:
Bo-Eric Persson, Neal D. Shore, Jens-Kristian Jensen, Laurent Boccon-Gibod, Tine Kold Olesen, Bertrand Tombal, Judd W. Moul, Fritz H. Schröder, E. David Crawford, Kurt Miller
Publikováno v:
Journal of Urology. 186:889-897
Purpose: We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial. Materials and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4287f8e5c4dfa721487b4d8935e79f8b
https://doi.org/10.1016/j.juro.2011.04.083
https://doi.org/10.1016/j.juro.2011.04.083
Publikováno v:
Journal of Clinical Oncology. 36:198-198
198 Background: Morbidity and mortality amongst patients diagnosed with metastatic prostate cancer remains high and androgen deprivation therapy is the mainstay of hormonal treatments for these patients. The gonadotropin-releasing hormone (GnRH) anta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0041a26e5f4d8d3f2942f0ce55b39e06
https://doi.org/10.1200/jco.2018.36.6_suppl.198
https://doi.org/10.1200/jco.2018.36.6_suppl.198
Publikováno v:
Journal of urology, 184(6), 2313-2319. Elsevier Inc.
Purpose We assessed the cardiovascular safety profile of degarelix, a new gonadotropin-releasing hormone antagonist. Materials and Methods This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd9b9b5329b7d6b637ccdc6237943c3
https://doi.org/10.1016/j.juro.2010.08.012
https://doi.org/10.1016/j.juro.2010.08.012